Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Analysis of Maryland cancer patient participation in national cancer institute-supported cancer treatment clinical trials.

Baquet CR, Ellison GL, Mishra SI.

J Clin Oncol. 2008 Jul 10;26(20):3380-6. doi: 10.1200/JCO.2007.14.6027. Erratum in: J Clin Oncol. 2008 Nov 1;26(31):5142..

2.

Analysis of Maryland cancer patient participation in National Cancer Institute-supported cancer treatment clinical trials.

Baquet CR, Ellison GL, Mishra SI.

J Health Care Poor Underserved. 2009 May;20(2 Suppl):120-34.

3.

How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.

Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N, Ford L, McCabe M, Kaplan R, Smith M, Ungerleider R, Christian MC.

J Clin Oncol. 2002 Apr 15;20(8):2109-17.

PMID:
11956272
4.

Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities.

Stewart JH, Bertoni AG, Staten JL, Levine EA, Gross CP.

Ann Surg Oncol. 2007 Dec;14(12):3328-34.

PMID:
17682824
5.

Geographic proximity and racial disparities in cancer clinical trial participation.

Kanarek NF, Tsai HL, Metzger-Gaud S, Damron D, Guseynova A, Klamerus JF, Rudin CM.

J Natl Compr Canc Netw. 2010 Dec;8(12):1343-51.

6.

Representation of Asian Americans in clinical cancer trials.

Alexander GA, Chu KC, Ho RC.

Ann Epidemiol. 2000 Nov;10(8 Suppl):S61-67.

PMID:
11189094
7.

National cancer clinical trials: children have equal access; adolescents do not.

Bleyer WA, Tejeda H, Murphy SB, Robison LL, Ross JA, Pollock BH, Severson RK, Brawley OW, Smith MA, Ungerleider RS.

J Adolesc Health. 1997 Dec;21(6):366-73.

PMID:
9401854
8.
9.

Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Murthy VH, Krumholz HM, Gross CP.

JAMA. 2004 Jun 9;291(22):2720-6.

PMID:
15187053
10.

The impact of socioeconomic status and race on trial participation for older women with breast cancer.

Gross CP, Filardo G, Mayne ST, Krumholz HM.

Cancer. 2005 Feb 1;103(3):483-91.

11.

Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007.

Korn EL, Freidlin B, Mooney M, Abrams JS.

J Clin Oncol. 2010 Dec 10;28(35):5197-201. doi: 10.1200/JCO.2010.31.5382.

12.

Who enrolls onto clinical oncology trials? A radiation Patterns Of Care Study analysis.

Movsas B, Moughan J, Owen J, Coia LR, Zelefsky MJ, Hanks G, Wilson JF.

Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1145-50.

PMID:
17418963
13.

Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors.

Baquet CR, Commiskey P, Daniel Mullins C, Mishra SI.

Cancer Detect Prev. 2006;30(1):24-33.

14.

What factors influence minority use of National Cancer Institute-designated cancer centers?

Huang LC, Ma Y, Ngo JV, Rhoads KF.

Cancer. 2014 Feb 1;120(3):399-407. doi: 10.1002/cncr.28413.

15.

Five National Cancer Institute-designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials: a current view and opportunities for improvement.

Hawk ET, Habermann EB, Ford JG, Wenzel JA, Brahmer JR, Chen MS Jr, Jones LA, Hurd TC, Rogers LM, Nguyen LH, Ahluwalia JS, Fouad M, Vickers SM.

Cancer. 2014 Apr 1;120 Suppl 7:1113-21. doi: 10.1002/cncr.28571.

16.

Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials.

Tejeda HA, Green SB, Trimble EL, Ford L, High JL, Ungerleider RS, Friedman MA, Brawley OW.

J Natl Cancer Inst. 1996 Jun 19;88(12):812-6.

PMID:
8637047
17.

Enrollment and Racial Disparities in Cancer Treatment Clinical Trials in North Carolina.

Zullig LL, Fortune-Britt AG, Rao S, Tyree SD, Godley PA, Carpenter WR.

N C Med J. 2016 Jan-Feb;77(1):52-8. doi: 10.18043/ncm.77.1.52.

18.

Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials.

Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL.

J Natl Cancer Inst. 2015 Dec 29;108(2). pii: djv324. doi: 10.1093/jnci/djv324.

PMID:
26714555
19.

Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials.

Cheng SK, Dietrich MS, Dilts DM.

Clin Cancer Res. 2011 Apr 1;17(7):1947-55. doi: 10.1158/1078-0432.CCR-10-1730.

20.

Power of an effective clinical conversation: improving accrual onto clinical trials.

Parreco LK, DeJoice RW, Massett HA, Padberg RM, Thakkar SS.

J Oncol Pract. 2012 Sep;8(5):282-6. doi: 10.1200/JOP.2011.000478.

Supplemental Content

Support Center